A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease

BACKGROUND: The lipoprotein-associated phospholipase A(2) inhibitor (Lp-PLA(2)), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). METHODS: One hundred twenty-four subjects with possible mild AD and with neuroimaging evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher-Edwards, Gareth, De'Ath, Jeni, Barnett, Carly, Lavrov, Arseniy, Lockhart, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975052/
https://www.ncbi.nlm.nih.gov/pubmed/29854933
http://dx.doi.org/10.1016/j.trci.2015.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975052/
https://www.ncbi.nlm.nih.gov/pubmed/29854933
http://dx.doi.org/10.1016/j.trci.2015.06.003

Ejemplares similares